Here’s what you should know:
1. The company’s GAAP adjusted earnings were $432 million or $0.31 per share.
2. Boston Scientific Chairman CEO Mike Mahoney said in a statement, “Our strong results reflect our global team’s focused efforts to execute our category leadership strategy and advance the standard of care. Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market, enabling our customers to deliver life-changing care to millions of patients around the world.”
3. Boston Scientific’s endoscopy division increased sales from $403 million to $443 million.
4. The cardiovascular division led the quarter with $908 million in sales, up from $857 million.
5. Despite the strong quarter, Boston Scientific lowered its full-year guidance to between $9.79 billion and $9.83 billion. It was previously between $9.8 billion and $9.88 billion.
More articles on gastroenterology:
Enterome & Takeda to co-develop drug for Crohn’s disease: 5 insights
Dr. Richard Blumberg earns spot in National Academy of Medicine — 3 insights
Central Maine Healthcare adds medical director in Dr. Sean McGarr — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.